Clinical Trial: Bevacizumab for the Treatment of Corneal Neovascularization

Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Topical/Subconjunctival Injection of Bevacizumab(Avastin) for the Treatment of Corneal Neovascularization

Brief Summary: The purpose of the current study is to assess the efficacy and safety of the inhibitory effect of bevacizumab (Avastin) with different routes including topical and subconjunctival application on corneal neovascularization in the human eyes.

Detailed Summary: The compassionate off-label use of bevacizumab as well as the potential risks, benefits, and adverse effects of this medication are discussed extensively with each patient. To further minimize systemic absorption, silicone punctual plugs are placed in the lower eyelids. One group of patients apply topical bevacizumab, 1.0%(10mg/ml), 4 times of day. The other group of patients received subconjunctival injection of bevacizumab(2.5mg/0.1ml) once. The patients are examined at 1day, 1week, 2weeks, 3weeks, and 1month, then monthly till the corneal neovascularization are gone or reduced to some degrees. Best-corrected visual acuity, slip-lamp examination, tonometry, external photography, pachymetry, specular microscopy (if possible), and systemic blood pressure are completed at all visits.
Sponsor: Chang Gung Memorial Hospital

Current Primary Outcome: Regression of corneal neovascularization [ Time Frame: 6 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome: visual acuity, lipid keratopathy, side effect [ Time Frame: 6 months ]

Original Secondary Outcome: Same as current

Information By: Chang Gung Memorial Hospital

Dates:
Date Received: October 8, 2009
Date Started: May 2009
Date Completion: April 2012
Last Updated: October 13, 2009
Last Verified: October 2009